Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for OVID.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2017. Start Trial.
Date Value
June 30, 2026 209.89M
March 31, 2026 198.27M
December 31, 2025 130.66M
September 30, 2025 44.70M
June 30, 2025 55.79M
March 31, 2025 59.28M
December 31, 2024 68.23M
September 30, 2024 76.29M
June 30, 2024 88.90M
March 31, 2024 78.28M
December 31, 2023 87.80M
September 30, 2023 101.29M
June 30, 2023 110.70M
March 31, 2023 120.95M
December 31, 2022 132.27M
September 30, 2022 142.05M
June 30, 2022 152.15M
March 31, 2022 165.00M
December 31, 2021 179.75M
Date Value
September 30, 2021 197.02M
June 30, 2021 206.71M
March 31, 2021 221.11M
December 31, 2020 43.63M
September 30, 2020 63.64M
June 30, 2020 30.48M
March 31, 2020 51.44M
December 31, 2019 70.02M
September 30, 2019 30.05M
June 30, 2019 45.44M
March 31, 2019 57.25M
December 31, 2018 38.81M
September 30, 2018 49.97M
June 30, 2018 61.12M
March 31, 2018 72.09M
December 31, 2017 83.44M
September 30, 2017 92.96M
June 30, 2017 100.94M
March 31, 2017 42.34M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 1.307B
Alnylam Pharmaceuticals, Inc. 1.354B
Anika Therapeutics, Inc. 137.28M
Savara, Inc. 143.66M
Vericel Corp. 370.04M

Shareholders Equity (Quarterly) Related Metrics